TABLE 1.
Clinicopathological characteristics and p.T790 M status of patients with advanced lung adenocarcinoma and acquired resistance to first‐generation EGFR‐TKIs
|
Overall (n = 34) |
p.T790 M Mutation Status | |||
|---|---|---|---|---|
|
p.T790 M positive (n = 13) |
p.T790 M Negative (n = 21) |
P value (95% CI) |
||
| Age | 0.14(15.25–2.30) | |||
| Median (±SD) | 64.0 ± 12.4 | 60.0 ± 12.5 | 66.5 ± 12.0 | |
| Sex | 1.0 | |||
| Male | 15(44.1%) | 6(46.2%) | 9(42.9%) | |
| Female | 19(55.9%) | 7(53.8%) | 12(57.1%) | |
| Smoking status | 0.46(0.45–0.47) | |||
| Never | 22(64.7%) | 7(53.8%) | 15(69.6%) | |
| Former | 12(35.3%) | 6(46.2%) | 6(30.4%) | |
| Paired samples | 0.26(0.25–0.27) | |||
| Tumor | 13(38.2%) | 4(30.8%) | 9(42.9%) | |
| Blood | 13(38.2%) | 4(30.8%) | 9(42.9%) | |
| Both tumor and blood | 8(23.5%) | 5 a (38.5%) | 3(14.3%) | |
| Status of other EGFR mutations rather than p.T790 M in paired samples | 0.89(0.89–0.90) | |||
| Exon 19 deletion | 18(52.9%) | 7(53.8%) | 11(52.4%) | |
| Exon 21 p.L858R | 15(44.1%) | 6(46.2%) | 9(42.9%) | |
| Exon 21 p.L861Q | 1(2.9%) | 0 | 1(4.8%) | |
| Sputum samples Cytological evaluation of the sputum samples | 0.60(0.59–0.61) | |||
| Malignant | 10(29.4%) | 4(30.8%) | 6(28.6%) | |
| Non‐malignant but satisfied | 18(52.9%) | 5(38.5.3%) | 13(61.9%) | |
| Unsatisfied | 6(17.6%) | 4(30.8%) | 2(9.5%) | |
a
One of the five patients had tumor p.T790 M positive but blood p.T790 M negative, the remaining four patients had both tumor and blood p.T790 M positive.